Novo Nordisk A/S (NVO)vsPDD Holdings Inc. (PDD)
NVO
Novo Nordisk A/S
$36.33
-1.52%
HEALTHCARE · Cap: $165.02B
PDD
PDD Holdings Inc.
$102.61
+4.61%
CONSUMER CYCLICAL · Cap: $139.25B
Smart Verdict
WallStSmart Research — data-driven comparison
PDD Holdings Inc. generates 35% more annual revenue ($418.54B vs $309.06B). NVO leads profitability with a 33.1% profit margin vs 24.4%. PDD appears more attractively valued with a PEG of 1.03. PDD earns a higher WallStSmart Score of 77/100 (B+).
NVO
Buy55
out of 100
Grade: C
PDD
Strong Buy77
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-59.4%
Fair Value
$24.21
Current Price
$36.33
$12.12 premium
Margin of Safety
+67.8%
Fair Value
$332.33
Current Price
$102.61
$229.72 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 61 in profit
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 44.5%
Large-cap with strong market position
Attractively priced relative to earnings
Every $100 of equity generates 31 in profit
Conservative balance sheet, low leverage
Generating 45.7B in free cash flow
Safe zone — low bankruptcy risk
Large-cap with strong market position
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Revenue declined 7.6%
Earnings declined 4.7%
No major concerns identified
Comparative Analysis Report
WallStSmart ResearchBull Case : NVO
The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.1% and operating margin at 44.5%.
Bull Case : PDD
The strongest argument for PDD centers on P/E Ratio, Return on Equity, Debt/Equity. Profitability is solid with margins at 24.4% and operating margin at 23.1%. PEG of 1.03 suggests the stock is reasonably priced for its growth.
Bear Case : NVO
The primary concerns for NVO are Piotroski F-Score, PEG Ratio, Revenue Growth.
Bear Case : PDD
No major red flags identified for PDD, but monitor valuation.
Key Dynamics to Monitor
NVO profiles as a declining stock while PDD is a mature play — different risk/reward profiles.
NVO carries more volatility with a beta of 0.27 — expect wider price swings.
PDD is growing revenue faster at 9.0% — sustainability is the question.
PDD generates stronger free cash flow (45.7B), providing more financial flexibility.
Bottom Line
PDD scores higher overall (77/100 vs 55/100), backed by strong 24.4% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
PDD Holdings Inc.
CONSUMER CYCLICAL · INTERNET RETAIL · China
Pinduoduo Inc., operates an electronic commerce platform in the People's Republic of China. The company is headquartered in Shanghai, the People's Republic of China.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?